Log in

NASDAQ:MYGN - Myriad Genetics Stock Price, Forecast & News

$14.06
-0.82 (-5.51 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$13.26
Now: $14.06
$14.88
50-Day Range
$9.78
MA: $16.89
$29.29
52-Week Range
$9.24
Now: $14.06
$48.40
Volume941,426 shs
Average Volume1.32 million shs
Market Capitalization$1.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency. In addition, Myriad Genetics, Inc. offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Read More
Myriad Genetics logo

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MYGN
CUSIP62855J10
Phone801-584-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$851.10 million
Cash Flow$2.20 per share
Book Value$14.84 per share

Profitability

Net Income$4.60 million

Miscellaneous

Employees2,600
Market Cap$1.05 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.


Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

How has Myriad Genetics' stock been impacted by COVID-19 (Coronavirus)?

Myriad Genetics' stock was trading at $14.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MYGN shares have increased by 0.2% and is now trading at $14.06. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Myriad Genetics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 3 sell ratings, 4 hold ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Myriad Genetics.

When is Myriad Genetics' next earnings date?

Myriad Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Myriad Genetics.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) issued its earnings results on Thursday, February, 6th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.01. The business had revenue of $195.10 million for the quarter, compared to the consensus estimate of $209.61 million. Myriad Genetics had a negative net margin of 3.22% and a positive return on equity of 5.42%. The company's revenue was down 10.0% on a year-over-year basis. During the same period last year, the business earned $0.38 earnings per share. View Myriad Genetics' earnings history.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics issued an update on its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share (EPS) guidance of approx $0.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.02. The company issued revenue guidance of approx $735 million, compared to the consensus revenue estimate of $807.66 million.

What price target have analysts set for MYGN?

8 analysts have issued 12-month price objectives for Myriad Genetics' stock. Their forecasts range from $10.00 to $36.00. On average, they expect Myriad Genetics' share price to reach $24.40 in the next twelve months. This suggests a possible upside of 73.6% from the stock's current price. View analysts' price targets for Myriad Genetics.

Has Myriad Genetics been receiving favorable news coverage?

News headlines about MYGN stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Myriad Genetics earned a coverage optimism score of -3.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutMyriad Genetics.

Are investors shorting Myriad Genetics?

Myriad Genetics saw a decline in short interest during the month of March. As of March 13th, there was short interest totaling 11,772,600 shares, a decline of 7.0% from the February 27th total of 12,660,000 shares. Based on an average trading volume of 1,119,000 shares, the short-interest ratio is currently 10.5 days. Approximately 16.3% of the company's shares are short sold. View Myriad Genetics' Current Options Chain.

Who are some of Myriad Genetics' key competitors?

What other stocks do shareholders of Myriad Genetics own?

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the following people:
  • Mr. Mark Christopher Capone, CEO, Pres & Director (Age 57)
  • Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 48)
  • Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 60)
  • Mr. Richard M. Marsh, Exec. VP, Gen. Counsel & Sec. (Age 61)
  • Mr. Alexander Ford, Pres of Myriad Women's Health (Age 52)

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (12.05%), State Street Corp (5.22%), Earnest Partners LLC (4.84%), Geode Capital Management LLC (1.41%), Bank of New York Mellon Corp (1.25%) and New York State Common Retirement Fund (1.23%). Company insiders that own Myriad Genetics stock include Bernard Tobin, Dennis Langer, Gary A King, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Nicole Lambert, Ralph L Mcdade, Richard Bryan Riggsbee, Richard M Marsh and Walter Phd Gilbert. View institutional ownership trends for Myriad Genetics.

Which major investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Baillie Gifford & Co., Royce & Associates LP, Man Group plc, Point72 Asset Management L.P., Russell Investments Group Ltd., AQR Capital Management LLC, and Bank of New York Mellon Corp. Company insiders that have sold Myriad Genetics company stock in the last year include Bernard Tobin, Gary A King, Nicole Lambert, and Richard Bryan Riggsbee. View insider buying and selling activity for Myriad Genetics.

Which major investors are buying Myriad Genetics stock?

MYGN stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, State Street Corp, Global Alpha Capital Management Ltd., Earnest Partners LLC, FMR LLC, Renaissance Technologies LLC, Great West Life Assurance Co. Can, and Credit Suisse AG. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, and Walter Phd Gilbert. View insider buying and selling activity for Myriad Genetics.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $14.06.

How big of a company is Myriad Genetics?

Myriad Genetics has a market capitalization of $1.05 billion and generates $851.10 million in revenue each year. The company earns $4.60 million in net income (profit) each year or $1.29 on an earnings per share basis. Myriad Genetics employs 2,600 workers across the globe. View additional information about Myriad Genetics.

What is Myriad Genetics' official website?

The official website for Myriad Genetics is http://www.myriad.com/.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]


MarketBeat Community Rating for Myriad Genetics (NASDAQ MYGN)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  444 (Vote Outperform)
Underperform Votes:  732 (Vote Underperform)
Total Votes:  1,176
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe MYGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: CD Ladder

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel